Nausea is the most common adverse effect, occurring in approximately 1525% of patients during clinical trials
GLP-1 (Glucagon-like peptide-1) medications, including Liraglutide and Semaglutide, are used primarily for the management of type 2 diabetes and weight loss
New Formulations: Efforts are underway to create more convenient formulations, including longer-acting injectables that may only require monthly administration and improved oral versions
Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, Ahn JM, Kiesewetter DO, Chen X
(Peptides Calculator) BiotechPeptides, Cell Aging Research and FOXO4-DRI Peptide. 2022